SCHEMBL5652928

SCHEMBL5652928

CCOc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2c(C)cccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
MGAM O43451 6/20 0.42
GAA P10253 6/20 0.42
SI P14410 6/20 0.42
MGAM2 Q2M2H8 6/20 0.42
APLNR P35414 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PDE5A O76074 1/20 0.38
HDAC1 Q13547 1/20 0.38
CBFB Q13951 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650016 0.90 MGAM (0.48) HPSESMN1; SMN2MGAMGAASI
SCHEMBL5650808 0.87 MGAM (0.48) HPSESMN1; SMN2HTTMGAMGAA
SCHEMBL5652807 0.87 PDE5A (0.53) SMN1; SMN2MEN1POLBHTTKMT2A
SCHEMBL5651271 0.84 MGAM (0.50) HPSESMN1; SMN2MGAMGAASI
SCHEMBL5652484 0.84 HPSE (0.48) HPSESMN1; SMN2HTTMGAMGAA
SCHEMBL5650806 0.83 SIRT2 (0.46) HPSESMN1; SMN2MEN1POLBHTT
SCHEMBL5650184 0.83 HPSE (0.45) HPSESMN1; SMN2MEN1POLBHTT
SCHEMBL5648605 0.81 RHEB (0.45) HPSESMN1; SMN2MEN1POLBHTT
SCHEMBL5651542 0.81 KMT2A (0.42) HPSESMN1; SMN2MEN1POLBHTT
SCHEMBL5652546 0.80 CNR1 (0.42) SMN1; SMN2MEN1POLBHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 HPSE 3728/4885SMN1; SMN2 1510/4885MEN1 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.